中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

10 records (took 0.013 seconds)

    NUCLEIC ACID CONSTRUCT COMPRISING 5' UTR STEM-LOOP FOR IN VITRO AND IN VIVO GENE EXPRESSION
    1.
    发明申请
    NUCLEIC ACID CONSTRUCT COMPRISING 5' UTR STEM-LOOP FOR IN VITRO AND IN VIVO GENE EXPRESSION 有权

    公开(公告)号：US20220267782A1

    公开(公告)日：2022-08-25

    申请号：US17596781

    申请日：2020-06-19

    Applicant: Glycom A/S

    Inventor： Margit PEDERSEN

    IPC: C12N15/70 ,  C12N15/113

    Abstract: The present invention relates to the field of recombinant production of biological molecules in host cells. The invention provides nucleic acid constructs that allow to modify expression of a desired gene using both in vitro and in vivo gene expression systems with optimized stem-loop structures in the 5′ UTR of said genes. The constructs can advantageously be used to produce a variety of biological molecules recombinantly in industrial scales, e.g. human milk oligosaccharides (HMOs)

    A DFL-PRODUCING STRAIN
    2.
    发明公开
    A DFL-PRODUCING STRAIN 审中-公开

    公开(公告)号：US20240043891A1

    公开(公告)日：2024-02-08

    申请号：US18258770

    申请日：2021-12-21

    Applicant: GLYCOM A/S

    Inventor： Margit PEDERSEN

    IPC: C12P19/18 ,  C12N9/10

    CPC classification number: C12P19/18 ,  C12N9/1051 ,  C12Y204/01069 ,  C12Y204/01065

    Abstract: The present invention relates to a genetically modified cell expressing an α-1,2-fucosyltransferase and an α-1,3-fucosyltransferase, and a transporter protein of the major facilitator superfamily (MFS) and to a method for recombinant production of human milk oligosaccharides (HMOs) using said genetically modified cell. More particularly, the invention provides a method for recombinant production of and a genetically modified cell capable of producing difucosyllactose (DFL) as the most abundant HMO, with a relatively low content of 3-fucosyllactose (3FL) and/or 2′-fucosyllactose (2′FL).

    HMO PRODUCTION
    4.
    发明公开
    HMO PRODUCTION 审中-公开

    公开(公告)号：US20230227876A1

    公开(公告)日：2023-07-20

    申请号：US17759273

    申请日：2021-01-22

    Applicant: GLYCOM A/S

    Inventor： Margit PEDERSEN ,  Katrine Bych KAMPMANN

    IPC: C12P19/00 ,  C07K14/24

    CPC classification number: C12P19/00 ,  C07K14/24

    Abstract: The present invention relates to the field of recombinant production of biological molecules in host cells. More particularly it relates to a method for recombinant production of human milk oligosaccharides (HMO) using a genetically modified cell expressing a protein of the major facilitator superfamily (MFS).

    SYNTHESIS OF THE FUCOSYLATED OLIGOSACCHARIDE LNFP-V
    6.
    发明申请
    SYNTHESIS OF THE FUCOSYLATED OLIGOSACCHARIDE LNFP-V 有权

    公开(公告)号：US20220282262A1

    公开(公告)日：2022-09-08

    申请号：US17299583

    申请日：2019-12-04

    Applicant: GLYCOM A/S

    Inventor： Manos PAPADAKIS ,  Margit PEDERSEN

    IPC: C12N15/70 ,  C12N9/10 ,  C12P19/18

    Abstract: The present invention provides a method for biotechnological production of LNFP-V by using recombinant bacterial cells. LNFP-V is produced by using a polypeptide having an a1,3/4-fucosyl transferase activity and comprising or consisting of an amino acid sequence that has a sequence identity of at least 90% with amino acid sequence of SEQ ID No. 1 or 3.

    NUCLEIC ACID CONSTRUCT FOR IN VITRO AND IN VIVO GENE EXPRESSION
    7.
    发明申请
    NUCLEIC ACID CONSTRUCT FOR IN VITRO AND IN VIVO GENE EXPRESSION 有权

    公开(公告)号：US20210102216A1

    公开(公告)日：2021-04-08

    申请号：US16956092

    申请日：2018-12-19

    Applicant: GLYCOM A/S

    Inventor： Margit PEDERSEN ,  Manos PAPADAKIS

    IPC: C12N15/70

    Abstract: The present invention relates to the field of recombining production of biological molecules in host cells. The invention provides nucleic acid constructs that allow to modify expression of a desired gene using both in vitro and in vivo gene expression systems. The constructs can advantageously be used to produce a variety of biological molecules recombinantly in industrial scales, e.g. human milk oligosaccharides (HMO).

Patent Agency Ranking